Efficacy and Safety of Co-Formulated Ombitasvir/Paritaprevir/Ritonavir with Ribavirin in Adults with Chronic HCV Genotype 4 Infection in Egypt (AGATE-II) [Abstract 708]

Esmat GE, Doss WH, Qaqish RB, Waked I, Shiha GE, Yosry A, et al. Efficacy and Safety of Co-Formulated Ombitasvir/Paritaprevir/Ritonavir with Ribavirin in Adults with Chronic HCV Genotype 4 Infection in Egypt (AGATE-II) [Abstract 708]. In 66th Annual Meeting of the American Association for the Study of Liver Diseases (AASLD), November 13-17, 2015. San Francisco, CA; 2015.

Publication Type:

Conference Paper

Authors:

Gamal E. Esmat; Wahid H. Doss; Roula B. Qaqish; Imam Waked; Gamal E. Shiha; Ayman Yosry; Mohamad Hassany; Jennifer King; Coleen Hall; Rebecca Redman; Niloufar Mobashery

Source:

66th Annual Meeting of the American Association for the Study of Liver Diseases (AASLD), November 13-17, 2015, Number 708, San Francisco, CA (2015)

Other Number:

Abstract 708

Abstract:

708

Cited On:

Export Citation:
RIS Format
Top